WP
SABS icon

Woodline Partners’s SAB Biotherapeutics SABS Stock Holding History

Woodline Partners’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.9M Buy
2,851,791
+910
+0% +$3.63K 0.04% 491
2025
Q4 		$10.7M Hold
2,850,881
– – 0.04% 445
2025
Q3 		$5.73M Buy
+2,850,881
New +$6.45M 0.03% 539

Other funds holding SABS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SSC
Spruce Street Capital New York $416M AUM

Woodline Partners's SABS Position: Q1 2026 in Review

Woodline Partners increased its SAB Biotherapeutics (SABS) stake by 0.03% in Q1 2026, buying an estimated $3.63K and bringing the position to 2,851,791 shares worth $10.9M. The position accounts for 0.04% of the portfolio, ranked #491.

Woodline Partners first reported a position in SABS in Q3 2025 and has held it in 3 quarters since. 76 funds tracked by Wall St. Rank hold SABS as of Q1 2026.

  • Woodline Partners held 2,851,791 shares of SAB Biotherapeutics worth $10.9M as of Q1 2026.
  • Woodline Partners bought 910 SAB Biotherapeutics shares in Q1 2026, an estimated $3.63K.
  • SAB Biotherapeutics made up 0.04% of Woodline Partners's portfolio in Q1 2026, its #491 holding.
  • Woodline Partners first reported a position in SAB Biotherapeutics in Q3 2025 and has held it in 3 quarters since.
  • 76 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.